Men with metastatic castration-resistant prostate cancer should be treated primarily with second-generation hormone drugs, which offer better treatment response and longer life expectancy than chemotherapy. However, the effect ...
Aug 20, 2024
0
51
Published today in Cancer Cell, results of a study directed by Joaquin Mateo, Head of the Vall d'Hebron Institute of Oncology's (VHIO) Prostate Cancer Translational Research Group, show that DNA/RNA material contained in ...
Jul 8, 2024
0
54
A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment. Utilizing lead-212 (212Pb), ...
Apr 16, 2024
0
33
SYNC-T, an investigational therapy that combines a device-induced vaccination at the tumor site with intratumoral infusion of a multitarget biologic drug led to numerous clinical responses in patients with metastatic castrate-resistant ...
Apr 8, 2024
0
30
